A Trans-amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity

• Published in: Molecular therapy Vol. 28; no. 1; pp. 119 - 128
• Main Authors: Beissert, Tim, Perkovic, Mario, Vogel, Annette, Erbar, Stephanie, Walzer, Kerstin C., Hempel, Tina, Brill, Silke, Haefner, Erik, Becker, René, Türeci, Özlem, Sahin, Ugur
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 08.01.2020; Elsevier Limited; American Society of Gene & Cell Therapy
• Subjects: alphavirus; Animals; Antibodies, Neutralizing - immunology; Antibodies, Viral - immunology; Antigens; Cricetinae; Dogs; Efficiency; Female; Genes; Genetic Vectors; HEK293 Cells; Hemagglutinin Glycoproteins, Influenza Virus - immunology; Hemagglutinins; Humans; Immune response; Immunogenicity, Vaccine; Influenza; Influenza A Virus, H1N1 Subtype - immunology; influenza vaccine; Influenza Vaccines - administration & dosage; Influenza Vaccines - immunology; Influenza, Human - metabolism; Influenza, Human - virology; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; mRNA; mRNA vaccines; Original; Orthomyxoviridae Infections - prevention & control; Orthomyxoviridae Infections - virology; Proteins; Replicase; replicon; RNA polymerase; RNA vaccine; RNA, Viral - genetics; saRNA; Semliki forest virus - genetics; taRNA; trans-replication; Vaccination; vaccine; Vaccines; Viral Replicase Complex Proteins - genetics; Viruses; influenza vaccine; vaccine; RNA vaccine; replicon; saRNA; taRNA; trans-replication; alphavirus
• ISSN: 1525-0016; 1525-0024
• DOI: 10.1016/j.ymthe.2019.09.009

Here, we present a potent RNA vaccine approach based on a novel bipartite vector system using trans-amplifying RNA (taRNA). The vector cassette encoding the vaccine antigen originates from an alphaviral self-amplifying RNA (saRNA), from which the replicase was deleted to form a transreplicon. Replicase activity is provided in trans by a second molecule, either by a standard saRNA or an optimized non-replicating mRNA (nrRNA). The latter delivered 10- to 100-fold higher transreplicon expression than the former. Moreover, expression driven by the nrRNA-encoded replicase in the taRNA system was as efficient as in a conventional monopartite saRNA system. We show that the superiority of nrRNA- over saRNA-encoded replicase to drive expression of the transreplicon is most likely attributable to its higher translational efficiency and lack of interference with cellular translation. Testing the novel taRNA system in mice, we observed that doses of influenza hemagglutinin antigen-encoding RNA as low as 50 ng were sufficient to induce neutralizing antibodies and mount a protective immune response against live virus challenge. These findings, together with a favorable safety profile, a simpler production process, and the universal applicability associated with this bipartite vector system, warrant further exploration of taRNA. This study describes the development of trans-amplifying RNA, a bipartite vaccine vector derived from the alphaviral genome. This vector induced protective immune response in mice to influenza HA with only 50 ng of antigen encoding RNA, a 400× lower dose compared to mRNA and 25× lower compared to self-amplifying RNA.